Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

NCT00608777 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Withdrawal of marketing autorization of efalizumab by the EMEA.

Conditions

Plaque Psoriasis

Interventions

DRUG: Calcipotriene/betamethasone

Sponsor

Derm Research, PLLC

Collaborators

[object Object]